Xanomeline Production Cost Reports

The report provides a detailed analysis essential for establishing a Xanomeline production plant. It encompasses all critical aspects necessary for Xanomeline production, including the cost of Xanomeline production, Xanomeline plant cost, Xanomeline production costs, and the overall Xanomeline production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Xanomeline production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Xanomeline is a novel muscarinic agonist that is used in combination with trospium chloride for treating schizophrenia in adults. It is the first antipsychotic that targets receptors rather than dopamine pathways to improve positive, negative, and cognitive symptoms. It works by activating central muscarinic acetylcholine receptors in the brain to modulate neurotransmitter circuits involving acetylcholine, dopamine, and glutamate. It helps in reducing hallucinations, delusions, and social withdrawal. It is taken twice-daily as oral dosing starting at 50 mg Xanomeline and 20 mg trospium, titrated to 100-125 mg and 20-30 mg as tolerated. Its common side effects include nausea, dyspepsia, constipation, vomiting, hypertension, abdominal pain, diarrhoea, increased heart rate, dizziness, and heartburn.

The market for Xanomeline is driven by growing cases of schizophrenia prevalence. Its innovative muscarinic agonist mechanism contributes to its demand to bypass D2 receptor blockade and associated antipsychotic side effects like weight gain and metabolic issues. Also,  strong clinical trial efficacy and FDA approval make it useful in schizophrenia treatment. The need for tolerable therapies beyond generic atypicals, fuelled by commercialisation and emerging real-world adoption, makes it a popular option. The industrial Xanomeline procurement is affected by fluctuating API pricing influenced by market dynamics, strict regulatory compliance (USDMF and GMP mandates), and limited global suppliers without CEP and JDMF certifications. Also, challenges like competition from low-cost generics, reimbursement hurdles, pricing pressures, and contraindications for chronic use further impact its procurement and market dynamics.

Raw Material for Xanomeline Production

According to the Xanomeline production plant project report, the key raw materials used in the production of Xanomeline include Pyridine-3-Carbaldehyde, KCN, and Acetic Acid.

Production Process of Xanomeline

The extensive Xanomeline production cost report consists of the following major industrial production process:

1. From Pyridine-3-Carbaldehyde: The production process of Xanomeline involves several steps. It starts with pyridine-3-carbaldehyde, which reacts with KCN in acetic acid, followed by NH4Cl in aqueous NH4OH to get  2-amino-2-(3-pyridyl)acetonitrile. This is then cyclised to 3-chloro-4-(3-pyridyl)-1,2,5-thiadiazole using S2Cl2 in DMF. This intermediate reacts with sodium hexyloxide in hexanol to form 3-(hexyloxy)-4-(3-pyridyl)-1,2,5-thiadiazole, which is quaternised with methyl iodide in acetone to the N-methylpyridinium salt. Finally, it is reduced with NaBH4 in ethanol to get Xanomeline.

Xanomeline is an off-white to white or yellow crystalline solid or powder with molecular formula C14H23N3OS and a molecular weight of 281.42 g/mol. It has a density of 1.101 g/cm³ and a logP value of 3.15-3.77 and a pKa value of 6.7-7.34. It has a boiling point of 397 degree Celsius and a flash point of 193.9 degree Celsius. It has a vapour pressure of 1.64E-06 mmHg at 25 degree Celsius and a refractive index of 1.537. Its topological polar surface area is 66.5 Ų with 0 hydrogen bond donors, 5 acceptors, and 7 rotatable bonds. Its water solubility is around 10 mg/mL, which makes it lipophilic with muscarinic agonist properties. It is stored by sealing at 2-8 degree Celsius.